Project Grant R01AI175949
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$862K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
This $814,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen clearance, which can lead to a clinical cure for chronic HBV infection. The principal investigators at the University of California, San Francisco (UCSF) will leverage mouse models and clinical samples from HBV patients to conduct a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research aimed at disrupting the formation of HBV cccDNA to combat chronic HBV infection, particularly in the context of HIV co-infection. The key objectives are to: 1) determine whether genetic disruption of host factors involved in HBV cccDNA...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $756,589 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Utah State University to develop a Syrian hamster model for Hepatitis B Virus (HBV) infection. The project aims to: 1) Establish a humanized-NTCP hamster model susceptible to HBV infection; 2) Characterize acute and chronic HBV infection pathogenesis and immune responses in the hamster model; and 3) Test antiviral drugs,...
The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $844,954.00 to New York University (NYU) to develop "Genomically Rewritten and Tailored Humanized Mouse Models for Various Organ Disorders". The project leverages NYU's expertise in advanced DNA synthesis and editing to create mouse models that accurately represent human disease genetics and phenotypes. These "GREAT-GEMMS" (Genomically...
This Project Grant award of $470,553 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Emory University aims to elucidate the genetic factors regulating the immune response to factor VIII (FVIII) in patients with hemophilia A. The research will use a genetically diverse mouse model to identify key genetic traits that influence the development of anti-FVIII antibodies, which can render FVIII replacement therapy...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing a potentially curative gene editing therapy for latent Herpes Simplex Virus Type 2 (HSV-2) infection. The $303,731 award to Caladan Therapeutics, Inc. aims to select and validate a lead meganuclease variant that can specifically target and eliminate HSV-2 from latently infected ganglionic neurons, which...